Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
5
×
life sciences
5
×
merck
5
×
national
national blog main
national top stories
new york blog main
new york top stories
pembrolizumab
5
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
cancer
cancer immunotherapy
clinical trials
fda
gene therapy
medicare
abbvie
affordable care act
alzheimer's disease
biogen
blueprint medicines
What
bio
roundup
drug
companies
nash
new
acquisitions
albert
american
approval
approved
arena’s
based
best
biggest
biogen’s
biopharmaceutical
bounty
bourla
cancer
ceo
cig
comeback
company
continue
convo
corner
crash
crispr
deals
debate
deeper
delivered
dna
earlier
expressing
failures
fda
fingerprint
future
Language
unknown
Current search:
merck
×
pembrolizumab
×
" indiana top stories "
×
" life sciences "
×
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More